Abstract
Novel inhibitors of Trypanosoma brucei and mammalian UDP-Glc 4'-epimerase were identified by screening a small library of natural products and commercially available drug-like molecules. The inhibitors possess low micromolar potency against the T brucei and human enzymes in vitro, display a degree of selectivity between the two enzymes, and are cytotoxic to cultured T. brucei and mammalian cells. (c) 2006 Elsevier Ltd. All rights reserved.
| Original language | English |
|---|---|
| Pages (from-to) | 5744-5747 |
| Number of pages | 4 |
| Journal | Bioorganic & Medicinal Chemistry Letters |
| Volume | 16 |
| Issue number | 22 |
| DOIs | |
| Publication status | Published - 15 Nov 2006 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Identification of novel inhibitors of UDP-Glc 4 '-epimerase, a validated drug target for African sleeping sickness'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver